Rep. Kevin Hern Sells Kenvue Inc. (NYSE:KVUE) Stock
by Teresa Graham · The Cerbat GemRepresentative Kevin Hern (Republican-Oklahoma) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on August 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Kenvue stock on August 5th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.
Representative Kevin Hern also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Diageo (NYSE:DEO) on 8/5/2026.
- Sold $1,001 – $15,000 in shares of Estee Lauder Companies (NYSE:EL) on 8/5/2026.
- Sold $1,001 – $15,000 in shares of Organon & Co. (NYSE:OGN) on 8/5/2026.
- Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 8/5/2026.
- Sold $1,001 – $15,000 in shares of Versant (NASDAQ:VSNT) on 8/5/2026.
- Sold $1,001 – $15,000 in shares of Comcast (NASDAQ:CMCSA) on 8/5/2026.
Kenvue Trading Down 0.4%
NYSE KVUE opened at $18.97 on Thursday. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The stock’s 50-day simple moving average is $18.88 and its two-hundred day simple moving average is $18.12. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $21.95. The company has a market capitalization of $36.44 billion, a price-to-earnings ratio of 21.80, a PEG ratio of 1.36 and a beta of 0.47.
Kenvue (NYSE:KVUE – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.Kenvue’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 earnings per share. Research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be paid a $0.21 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date of this dividend is Wednesday, August 12th. Kenvue’s payout ratio is currently 95.40%.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Kenvue by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock valued at $4,052,913,000 after buying an additional 1,604,040 shares during the period. BlackRock Inc. bought a new position in Kenvue in the 2nd quarter worth $2,882,279,000. State Street Corp boosted its stake in shares of Kenvue by 3.5% during the 4th quarter. State Street Corp now owns 118,865,134 shares of the company’s stock valued at $2,050,424,000 after purchasing an additional 4,063,257 shares in the last quarter. Geode Capital Management LLC boosted its position in Kenvue by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock valued at $856,778,000 after acquiring an additional 371,322 shares in the last quarter. Finally, Independent Franchise Partners LLP lifted its position in Kenvue by 56.3% during the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after buying an additional 17,343,785 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Analyst Ratings Changes
A number of brokerages have recently weighed in on KVUE. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. UBS Group decreased their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Tuesday. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Barclays upped their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Three analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $19.27.
Read Our Latest Analysis on KVUE
About Representative Hern
Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.
Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.
Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.
Kenvue Company Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.